WAT Medical's Innovative Approach to Postoperative Nausea
WAT Medical is excited to announce a pivotal advancement in postoperative care with their EmeTerm wristband, which utilizes innovative technology to aid patients suffering from moderate to severe postoperative nausea and vomiting (PONV). This non-invasive device employs transcutaneous electrical stimulation to deliver improved outcomes compared to traditional medication options like metoclopramide.
Significant Findings from the Clinical Trial
The recent study published in JAMA Surgery involved 232 female patients who faced moderate to severe PONV following significant surgeries. Conducted in multiple prestigious hospitals, this trial was designed to evaluate the efficacy of EmeTerm against a placebo-control with metoclopramide.
Study Design and Methodology
The participants were randomly assigned to either receive the EmeTerm device, strategically stimulating acupoint PC6 on the median nerve, or a control group that received a sham device along with metoclopramide. This double-blind setup ensured unbiased results and maximum reliability.
Key Metrics Assessed
The primary goal was to measure the remission rate of nausea within two hours post-operation, while secondary metrics included the relapse rates over the following 24 hours and the crossover response of patients experiencing continued nausea.
Outcomes That Matter
The results were overwhelmingly positive for the EmeTerm device:
- 2-Hour Remission Rate: Patients using EmeTerm showed a remarkable remission rate of 77.6%, significantly higher than the 55.2% seen with metoclopramide (P < 0.001).
- 24-Hour Relapse Rate: Additionally, the relapse rate for those using EmeTerm was considerably lower at 12.2% compared to 56.3% for those on metoclopramide (P < 0.001).
- Safety Profile: Importantly, no serious adverse effects were noted from EmeTerm, underscoring its safety as a viable treatment option.
These findings illuminate the potential of EmeTerm as a frontline treatment for PONV, suggesting a paradigm shift towards non-pharmacological options that prioritize patient wellbeing. With fewer side effects and sustained relief, patients are likely to engage in quicker recovery.
The Path Forward for WAT Medical
Developed by WAT Medical Enterprise Ltd., the EmeTerm device not only represents innovation in nausea management but also showcases the company’s dedication to enhancing recovery strategies in clinical settings. The device has achieved key international regulatory approvals, highlighting its commitment to safety and efficacy in various countries including the U.S. and Australia.
The publication of the trial results in a prestigious journal like JAMA Surgery underscores the rigorous research behind EmeTerm and its growing adoption worldwide among healthcare professionals seeking effective solutions for PONV management.
Frequently Asked Questions
What is the EmeTerm device?
The EmeTerm device is a wearable solution developed by WAT Medical that uses transcutaneous electrical acupoint stimulation to treat postoperative nausea and vomiting.
How does EmeTerm compare to metoclopramide?
In clinical trials, EmeTerm demonstrated superior efficacy with higher remission rates and lower relapse rates compared to metoclopramide.
Is EmeTerm safe for patients?
Yes, the clinical trials reported no serious adverse events linked to the use of the EmeTerm device.
Where has EmeTerm been approved?
The device has received regulatory approval from health authorities in the U.S., Canada, and Australia.
How can healthcare providers access EmeTerm?
Healthcare providers interested in EmeTerm for their patients can consult WAT Medical for information on procurement and clinical guidelines.
